U.S., March 21 -- ClinicalTrials.gov registry received information related to the study (NCT06886347) titled 'Metastatic Nasopharyngeal Carcinoma' on July 11, 2023.
Brief Summary: To evaluaate the efficacy and safety of the regimen incuding Penpulimab, Gemcitabine and Anlotinib in the treatment of metastatic nasopharyngeal carcinoma. Using Progression-Free-Survival as the primary endpoint.
Study Start Date: July 07, 2023
Study Type: INTERVENTIONAL
Condition:
Metastatic Nasopharyngeal Carcinoma
Intervention:
DRUG: Penplimab Injection
Penplimab Injection: Intravenous infusion of Penplimab 200 mg Q3W, with a 3-week treatment cycle.
Anlotinib Hydrochloride Capsules: 10 mg, taken orally on an empty stomach before breakfast once a day (t...